Kainova Therapeutics
Illkirch · Founded 2001
About Kainova Therapeutics
Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-All™ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-All™ is able to address difficult GPCRs such as orphan and peptidic GPCRs.
Company Facts
- Founded: 2001
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $123.6M
- Funding stage: Early Stage Venture
- Last round: Series B (Feb 2026)
- Website: http://www.domaintherapeutics.com
- Phone: +33 3 90 40 61 50
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/kainova-therapeutics-82815 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.